Brain Wealthy
    What's Hot

    Review: Never Sleep Again: The Elm Street Legacy – Blu-ray

    February 2, 2023

    Gardasil Injection Lawsuit Claims HPV Vaccine Caused Neurological and Autonomic Dysfunction

    February 2, 2023

    Research project applies a global lens to student mental health

    February 2, 2023
    Facebook Twitter Instagram
    Facebook Twitter Instagram
    Brain Wealthy
    • Home
    • Anxiety

      FSU psychologist receives $3.7 million grant to combat anxiety in seniors with Alzheimer’s and cognitive impairment

      February 2, 2023

      How anxiety came to dominate the big business of medical marijuana cards in Pa.

      February 2, 2023

      How to Reduce Anxiety in Stressful Situations

      February 2, 2023

      The cat in boots The last wish taught me about anxiety

      February 2, 2023

      Inseparable cat trio with ‘separation anxiety brothers’ find new home

      February 2, 2023
    • Emotion

      Ontario paramedic emotional during last radio call

      February 2, 2023

      A Pianist Faces Death and Recorded Music of Unspeakable Emotions

      February 2, 2023

      Return of home post linking Gichaara to ancestors is emotional for north coast nation

      February 2, 2023

      Mother of two sues New York school district for ‘mental distress’ caused by mask enforcement

      February 2, 2023

      Emotional (mis)perceptions: Is the EU missing the mark?

      February 2, 2023
    • Neurology

      Gardasil Injection Lawsuit Claims HPV Vaccine Caused Neurological and Autonomic Dysfunction

      February 2, 2023

      REGENXBIO’s Duchenne Therapy RGX-202 Clinical Trial Begins Patient Recruitment

      February 2, 2023

      Aducanumab for the treatment of Alzheimer’s disease

      February 2, 2023

      Potential for Effective Comparative Studies and Treatment Approval in Epilepsy Care: Anup Patel, MD

      February 2, 2023

      Head injury does not predict memory impairment in NFL retirees, UT Southwestern study shows: Newsroom

      February 2, 2023
    • Sleep

      Review: Never Sleep Again: The Elm Street Legacy – Blu-ray

      February 2, 2023

      Get a better night’s sleep with better pillows from The Pillow Bar in Dallas

      February 2, 2023

      Is it okay to sleep with a necklace on?

      February 2, 2023

      Does tart cherry juice improve sleep?

      February 2, 2023

      Social Jet Lag, Sleep Chronotypes, and Why We Gotta Close Our Eyes and Embrace It

      February 2, 2023
    • Brain Research

      spark!Talk – video available online

      February 2, 2023

      Studies have found that obesity-related neurodegeneration mimics Alzheimer’s disease.newsroom

      February 2, 2023

      The Brain Observatory: New Museum to Participate in Museum Month

      February 1, 2023

      who wants to live forever

      February 1, 2023

      UK company makes surprise forays

      February 1, 2023
    • Brain Wealth
      1. Mental Health
      2. View All

      Research project applies a global lens to student mental health

      February 2, 2023

      DC Metro shooting suspect undergoes mental health evaluation after rampage

      February 2, 2023

      Gov. Ho-Chol unveils details of $1 billion plan to overhaul New York State’s mental health care continuum

      February 2, 2023

      Boston, we have a problem: data on mental health and practice come in

      February 2, 2023

      Research project applies a global lens to student mental health

      February 2, 2023

      DC Metro shooting suspect undergoes mental health evaluation after rampage

      February 2, 2023

      Gov. Ho-Chol unveils details of $1 billion plan to overhaul New York State’s mental health care continuum

      February 2, 2023

      Boston, we have a problem: data on mental health and practice come in

      February 2, 2023
    Brain Wealthy
    Home»Neurology»The Most Important Neurological Research of 2022
    Neurology

    The Most Important Neurological Research of 2022

    brainwealthy_vws1exBy brainwealthy_vws1exDecember 30, 2022No Comments5 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    This transcript has been edited for clarity.

    Dear Colleagues, I am Christoph Diener from the University of Duisburg-Essen, Germany. The goal of my video this month is to summarize the most important clinical studies in neurology published in 2022.

    Warnings about lecanemab

    I would like to begin by discussing a publication in The New England Journal of Medicine on Alzheimer’s disease.

    This study investigated lecanemab, a monoclonal antibody against beta-amyloid in people with mild cognitive impairment or early Alzheimer’s disease. Results showed that a monoclonal antibody against beta-amyloid was effective on both primary and secondary endpoints of cognition and function.

    The data on amyloid on PET were most impressive. The amyloid burden in the brain remained unchanged in placebo-treated patients. However, the monoclonal antibody treatment group reduced brain amyloid concentrations by 60% to 70% within 18 months.

    At present, we do not know how this translates into clinical benefit over the years. But the most important message here is that for the first time in history, we have a drug that slows the progression of early Alzheimer’s disease. .

    There are also warnings that are adverse event profiles. These monoclonal antibodies can cause brain edema, requiring an MRI every three months. It can also cause minor bleeding, which is usually asymptomatic. No one knows what will happen to patients who need anticoagulant therapy because they have atrial fibrillation and who take these drugs for a long period of time.

    COVID-19 and physical symptoms

    Let’s move on to the post-COVID-19 setting.

    We are currently conducting a number of studies looking at people who have and are in control of COVID-19 and who are being monitored for physical symptoms. Most of the physical symptoms are in the neurological realm. Headache, fatigue, dizziness, back pain, muscle pain, and nausea.

    One of the studies in the Netherlands examined the post-COVID-19 state while correcting for individual symptoms that existed before COVID-19 and the symptom dynamics of the SARS-CoV-2-free population during the pandemic. It is the first to report the nature and prevalence. About 20% of people infected with COVID-19 developed physical symptoms 90 to 150 days after infection, compared to only 9% of controls.

    Unfortunately, the pathophysiology of this post-COVID-19 syndrome is unknown and there are no real effective treatments.

    Need for new sleeping pills

    Now let’s move on to sleep disorders.

    We used to have benzodiazepines, but they have been replaced by the Z substance. Although Substance Z was not thought to lead to addiction, some patients have become addicted.

    A new class of drugs is the orexin antagonists. Daridorexant is a dual orexin antagonist that has shown efficacy in two large Phase 3 trials. The good news here is that not only did the drug improve the latency for patients to fall asleep, but it also had no hangover effect the next day.

    Epstein-Barr virus and multiple sclerosis

    The most controversial aspect of multiple sclerosis research came from a large study using the Veterans Administration database. Epstein-Barr virus infection was shown to significantly increase the risk of developing multiple sclerosis. In contrast, this was not the case for cytomegalovirus virus.

    Unfortunately, 70% to 80% of adults are infected with the Epstein-Barr virus, making it a very common infection. To date there is no vaccine, and it remains unknown whether vaccines really reduce the chances of multiple sclerosis.

    Parkinson’s disease treatment hits roadblocks

    Let’s move on to Parkinson’s disease.

    We know that α-synuclein aggregates in the brain are a clear pathophysiological factor in this disease. A group in Kiel, Germany, has developed a blood test that identifies alpha-synuclein in serum. That’s good news.

    The bad news is that two randomized, placebo-controlled trials in early-stage Parkinson’s disease patients using monoclonal antibodies to alpha-synuclein were negative. This means that there are currently no treatments with disease-modifying effects for Parkinson’s disease.

    Mechanical thrombectomy turns out to be superior in stroke

    Regarding stroke, we have two important updates.

    Several randomized studies have shown that the addition of thrombolytic therapy to precirculatory mechanical thrombectomy improves functional outcomes, reduces mortality, and increases reperfusion rates.

    We are currently conducting two randomized trials that clearly show that mechanical thrombectomy is superior to pure medical treatment in people with thrombosis or occlusion of the basilar artery.

    A step forward in migraine prophylaxis

    Headache at the end.

    The good news here is that monoclonal antibodies against CGRP or CGRP receptors are effective in treating chronic migraine. It is also effective for people who have failed previous treatments and for people with medication-overuse headaches. Also, there are almost no side effects.

    Besides being costly, this is a step forward in the specific treatment of migraine from a prophylactic therapy perspective.

    Colleagues, 2022 has been an exciting year. These are just some of the highlights. Thank you very much for watching and listening.

    See you in 2023!

    Follow Medscape on Facebook. twitterInstagram, YouTube





    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleI’m a sleep expert – exactly how long it takes before lack of quality snooze time is dangerous to your health
    Next Article Lack of sleep can harm a child’s brain and cognitive development
    brainwealthy_vws1ex
    • Website

    Related Posts

    Gardasil Injection Lawsuit Claims HPV Vaccine Caused Neurological and Autonomic Dysfunction

    February 2, 2023

    REGENXBIO’s Duchenne Therapy RGX-202 Clinical Trial Begins Patient Recruitment

    February 2, 2023

    Aducanumab for the treatment of Alzheimer’s disease

    February 2, 2023
    Add A Comment

    Leave A Reply Cancel Reply

    Top Posts

    Subscribe to Updates

    Get the latest sports news from SportsSite about soccer, football and tennis.

    This website provides information about Brain and other things. Keep Supporting Us With the Latest News and we Will Provide the Best Of Our To Makes You Updated All Around The World News. Keep Sporting US.

    Facebook Twitter Instagram Pinterest YouTube
    Top Insights

    Top UK Stocks to Watch: Capita Shares Rise as it Unveils

    January 15, 2021
    8.5

    Digital Euro Might Suck Away 8% of Banks’ Deposits

    January 12, 2021

    Oil Gains on OPEC Outlook That U.S. Growth Will Slow

    January 11, 2021
    Get Informed

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    © 2023 brainwealthy. Designed by brainwealthy.
    • Home
    • Contact us
    • DMCA
    • Privacy Policy

    Type above and press Enter to search. Press Esc to cancel.